Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Running, not enrolling · Phase 2

Conditions studied: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

In brief

The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.

Key facts

Study ID

NCT05458674

Run by

Criterium, Inc.

People needed

17

Starts

2024-01-30

Expected to finish

2027-08-01

Last updated by the study team

2026-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed HER2+ breast carcinoma, with HER2+ defined by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC)
• Have received previous treatment with trastuzumab deruxtecan in the metastatic setting or have recurred within 6 months of receiving this treatment in the adjuvant or neoadjuvant setting. Prior taxane, capecitabine and T-DM1 are not required. Prior tucatinib therapy is allowed. Patients for whom Trastuzumab is contraindicated are not permitted. Have progression of unresectable locally advanced or metastatic breast cancer after last systemic therapy (as confirmed by site investigator),or be intolerant of last systemic therapy.
• Have measurable or non-measurable disease assessable by RECIST 1.1
• Be at least 18 years of age at time of consent.
• Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0,1 or 2
• Have a life expectancy of at least 6 months, in the opinion of the site investigator.
• Have adequate hepatic function as defined by the following:
• Total bilirubin ≤1.5 X upper limit of normal (ULN), except for patients with known Gilbert's disease, who may enroll if the conjugated bilirubin is ≤1.5 X ULN
• Transaminases [aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)] ≤ 2.5 X ULN (≤ 5 X ULN if liver metastases are present)
• Have adequate baseline hematologic parameters as defined by:
• Absolute neutrophil count (ANC) ≥ 1.5 x 103/µL
• Platelet count ≥ 100 x 103/µL; patients with stable platelet count from 75- 100 x 103/µL may be included with approval from medical monitor,
• Hemoglobin ≥ 9 g/dL
• In patients transfused before study entry, transfusion must be ≥ 14 days prior to start of therapy to establish adequate hematologic parameters independent from transfusion support,
• Have creatinine clearance ≥ 50 mL/min as calculated per institutional guidelines or, in patients ≤ 45 kg in weight, a serum creatinine within institutional normal limits,
• International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 X ULN unless on medication known to alter INR and aPTT. (Note: Warfarin and other coumarin derivatives are prohibited.)
• Have left ventricular ejection fraction (LVEF) ≥ 50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented within 4 weeks prior to first dose of study treatment.
• If female of childbearing potential, must have a negative result of serum or urine pregnancy test performed within 7 days prior to first dose of study treatment. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post- menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
• NOTE: Postmenopausal patients with known β-HCG secreting tumors may be eligible when β-HCG-based urine or serum pregnancy tests yield false positive if they meet the definition of postmenopausal state and have a negative uterine ultrasound
• Women of childbearing potential (as defined above) and men with partners of childbearing potential must agree to use a highly effective birth control method, i.e., methods that achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal); progestogen- only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable); intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion/ligation; vasectomized partner; or sexual abstinence. Male patients with partners of childbearing potential must use barrier contraception. All study patients should practice effective contraception, as described above, starting from the signing of informed consent until 7 months after the last dose of study medication or investigational medicinal product.
• Patient must provide signed informed consent per a consent document that has been approved by an institutional review board or independent ethics committee (IRB/IEC) prior to initiation of any study-related tests or procedures that are not part of standard-of-care for the patient's disease.
• Patients must be willing and able to comply with study procedures.
• CNS Inclusion - Based on screening contrast brain magnetic resonance imaging (MRI), patients must have one of the following:
• No evidence of brain metastases
• Untreated brain metastases not needing immediate local therapy. For patients with untreated CNS lesions > 2.0 cm on screening contrast brain MRI, discussion with and approval from the medical monitor is required prior to enrollment,

You may not qualify if…

• Have previously been treated with eribulin for metastatic disease (except in cases where eribulin was given for ≤ 21 days and was discontinued for reasons other than disease progression or severe toxicity)
• History of exposure to the following cumulative doses of anthracyclines:
• Doxorubicin > 360 mg/m2
• Epirubicin > 720 mg/m2
• Mitoxantrone > 120 mg/m2
• Idarubicin > 90 mg/m2
• Liposomal doxorubicin (e.g. Doxil, Caelyx, Myocet) > 550 mg/m2
• History of allergic reactions to trastuzumab, eribulin, or compounds chemically or biologically similar to tucatinib, except for Grade 1 or 2 infusion related reactions to trastuzumab that were successfully managed, or known allergy to one of the excipients in the study drugs
• Have received treatment with any systemic anti-cancer therapy (including hormonal therapy), non-CNS radiation, or experimental agent ≤ 3 weeks of first dose of study treatment or are currently participating in another interventional clinical trial. An exception for the washout of hormonal therapies is gonadotropin releasing hormone (GnRH) agonists used for ovarian suppression in premenopausal women, which are permitted concomitant medications.
• Have any toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:
• alopecia and neuropathy, which must have resolved to ≤ Grade 2; and
• congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of occurrence, and must have resolved completely.
• anemia, which must have resolved to ≤ Grade 2
• Have clinically significant cardiopulmonary disease such as:
• ventricular arrhythmia requiring therapy,
• uncontrolled hypertension (defined as persistent systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 100 mm Hg on antihypertensive medications)
• any history of symptomatic CHF
• severe dyspnea at rest (CTCAE Grade 3 or above) due to complications of advanced malignancy
• hypoxia requiring supplementary oxygen therapy except when oxygen therapy is needed only for obstructive sleep apnea.
• Presence of Grade 2 or greater QTc prolongation on screening ECG.
• conditions potentially resulting in drug-induced prolongation of the QT interval or torsade de pointes:
• i. Congenital or acquired long QT syndrome. ii. Family history of sudden death iii. History of previous drug induced QT prolongation iv. Current use of medications with known and accepted associated risk of QT prolongation
• Have known myocardial infarction or unstable angina within 6 months prior to first dose of study treatment.
• Have chronic active Hepatitis B or Hepatitis C or have other known chronic liver disease.
• Are known to be positive for human immunodeficiency virus (HIV)

Where it is running

• University of Colorado — Aurora, Colorado, United States
• George Washington Medical Faculty Associates — Washington D.C., District of Columbia, United States
• New Mexico Cancer Care Alliance — Albuquerque, New Mexico, United States
• Swedish Cancer Institute — Issaquah, Washington, United States
• Cancer Care Northwest — Spokane Valley, Washington, United States
• University of Wisconsin Carbone Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.